secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001576885-25-000062
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Pharma Q1 net loss $28.8M; Phase 2 Alzheimer's trial fully enrolled, results late 2026
--------------------------------------------------------------------------------

- Net loss $28.8M in Q1 2025 ($14.9M Q1 2024); loss from operations $30.4M vs $17.8M.
- R&D expenses $25.3M (up 104% YoY) driven by ALTITUDE-AD Phase 2 clinical trial costs.
- Cash, cash equivalents and marketable securities $197.9M, expected to fund operations into early 2027.
- Phase 2 ALTITUDE-AD study of sabirnetug fully enrolled (542 participants); topline data readout late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000062/0001576885-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000062/abos-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001576885-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer